Want to see KROS full AI Analyst Report?
Keros Therapeutics (KROS) Stock Statistics & Valuation Metrics
Total Valuation
Keros Therapeutics has a market cap or net worth of $218.89M. The enterprise value is -$30.02M.
- Market Cap
- $218.89M
- Enterprise Value
- -$30.02M
Share Statistics
Keros Therapeutics has 19,827,188 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 19,827,188
- Owned by Insiders
- 5.14%
- Owned by Institutions
- 36.00%
Financial Efficiency
Keros Therapeutics’s return on equity (ROE) is 0.29 and return on invested capital (ROIC) is 20.90%.
- Return on Equity (ROE)
- 0.29
- Return on Assets (ROA)
- 0.26
- Return on Invested Capital (ROIC)
- 20.90%
- Return on Capital Employed (ROCE)
- 0.22
- Revenue Per Employee
- 2.65M
- Profits Per Employee
- 945.80K
- Employee Count
- 92
- Asset Turnover
- 0.72
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Keros Therapeutics is -2.98. Keros Therapeutics’s PEG ratio is 0.00.
- PE Ratio
- -2.98
- PS Ratio
- 14.58
- PB Ratio
- 0.83
- Price to FCF
- -4.51
- Price to Operating Cash Flow
- -4.55
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Keros Therapeutics had revenue of 244.06M and earned 87.01M in profits. Earnings per share was 2.34.
- Revenue
- 244.06M
- Gross Profit
- 242.55M
- Operating Income
- 70.62M
- Pretax Income
- 91.90M
- Net Income
- 87.01M
- EBITDA
- 93.41M
- Earnings Per Share (EPS)
- 2.34
Cash Flow
In the last 12 months, operating cash flow was -47.99M and capital expenditures -494,000, giving a free cash flow of -48.49M billion.
- Operating Cash Flow
- -47.99M
- Free Cash Flow
- -48.49M
- Free Cash Flow per Share
- -2.45
Dividends & Yields
Keros Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -22.15%
- Earnings Yield
- -38.04%
Stock Price Statistics
- Beta
- 1.32
- 52-Week Price Change
- -26.55%
- 50-Day Moving Average
- 11.28
- 200-Day Moving Average
- 11.94
- Relative Strength Index (RSI)
- 45.93
- Average Volume (3m)
- 188.78K
Important Dates
Keros Therapeutics upcoming earnings date is Nov 11, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 03, 2026
- Next Earnings Date
- Nov 11, 2026
- Ex-Dividend Date
- ―
Financial Position
Keros Therapeutics as a current ratio of 15.45, with Debt / Equity ratio of 5.57%
- Current Ratio
- 15.45
- Quick Ratio
- 15.45
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -2.90
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Keros Therapeutics has paid 4.88M in taxes.
- Income Tax
- 4.88M
- Effective Tax Rate
- 0.05
Enterprise Valuation
Keros Therapeutics EV to EBITDA ratio is 0.27, with an EV/FCF ratio of 0.47.
- EV to Sales
- -1.53
- EV to EBITDA
- 0.27
- EV to Free Cash Flow
- 0.47
- EV to Operating Cash Flow
- 0.48
Balance Sheet
Keros Therapeutics has $257.61M in cash and marketable securities with $15.72M in debt, giving a net cash position of $241.88M billion.
- Cash & Marketable Securities
- $257.61M
- Total Debt
- $15.72M
- Net Cash
- $241.88M
- Net Cash Per Share
- $12.20
- Tangible Book Value Per Share
- $13.25
Margins
Gross margin is 94.68%, with operating margin of -675.82%, and net profit margin of -553.88%.
- Gross Margin
- 94.68%
- Operating Margin
- -675.82%
- Pretax Margin
- -573.44%
- Net Profit Margin
- -553.88%
- EBITDA Margin
- -562.79%
- EBIT Margin
- -573.44%
Analyst Forecast
The average price target for Keros Therapeutics is $18.80, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $18.80
- Price Target Upside
- 70.29% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 6
- Revenue Growth Forecast
- -93.55%
- EPS Growth Forecast
- -1143.58%
Scores
- Smart Score
- 5
- AI Score
- 52
